Little House Capital LLC Has $1.55 Million Stock Holdings in Amgen Inc. (NASDAQ:AMGN)

Little House Capital LLC trimmed its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 24.1% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,456 shares of the medical research company’s stock after selling 1,734 shares during the quarter. Little House Capital LLC’s holdings in Amgen were worth $1,551,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its stake in shares of Amgen by 0.3% in the 3rd quarter. Vanguard Group Inc. now owns 49,035,981 shares of the medical research company’s stock worth $13,178,910,000 after acquiring an additional 165,636 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in shares of Amgen by 3.9% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 6,564,710 shares of the medical research company’s stock valued at $1,890,769,000 after acquiring an additional 243,720 shares in the last quarter. Royal Bank of Canada boosted its stake in Amgen by 14.8% in the fourth quarter. Royal Bank of Canada now owns 5,831,624 shares of the medical research company’s stock valued at $1,679,625,000 after acquiring an additional 751,947 shares during the last quarter. Norges Bank bought a new stake in shares of Amgen in the 4th quarter worth approximately $1,556,912,000. Finally, California Public Employees Retirement System grew its holdings in Amgen by 22.0% during the fourth quarter. California Public Employees Retirement System now owns 2,716,088 shares of the medical research company’s stock valued at $782,288,000 after purchasing an additional 490,539 shares during the period. Institutional investors own 76.50% of the company’s stock.

Insider Buying and Selling at Amgen

In other news, SVP Nancy A. Grygiel sold 2,117 shares of the company’s stock in a transaction dated Friday, May 3rd. The stock was sold at an average price of $313.09, for a total value of $662,811.53. Following the sale, the senior vice president now owns 9,883 shares in the company, valued at $3,094,268.47. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 0.69% of the company’s stock.

Amgen Stock Down 0.3 %

Amgen stock traded down $0.97 during mid-day trading on Monday, reaching $311.48. 873,025 shares of the company were exchanged, compared to its average volume of 2,775,958. The firm has a market cap of $167.09 billion, a P/E ratio of 44.64, a PEG ratio of 2.82 and a beta of 0.58. The company has a debt-to-equity ratio of 11.96, a quick ratio of 0.98 and a current ratio of 1.42. Amgen Inc. has a 12-month low of $218.44 and a 12-month high of $329.72. The business has a fifty day moving average of $301.56 and a 200 day moving average of $292.30.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Thursday, May 2nd. The medical research company reported $3.96 EPS for the quarter, beating the consensus estimate of $3.76 by $0.20. Amgen had a net margin of 12.74% and a return on equity of 156.21%. The business had revenue of $7.45 billion during the quarter, compared to analysts’ expectations of $7.45 billion. During the same period in the previous year, the business posted $3.98 EPS. The business’s quarterly revenue was up 22.0% compared to the same quarter last year. Research analysts anticipate that Amgen Inc. will post 19.47 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have recently commented on AMGN shares. Royal Bank of Canada upped their price target on Amgen from $328.00 to $332.00 and gave the company an “outperform” rating in a research report on Friday, June 14th. TD Cowen reduced their price objective on shares of Amgen from $370.00 to $360.00 and set a “buy” rating for the company in a research note on Wednesday, April 17th. Raymond James started coverage on shares of Amgen in a research note on Thursday, March 28th. They issued a “market perform” rating on the stock. William Blair raised shares of Amgen from a “market perform” rating to an “outperform” rating in a report on Friday, May 3rd. Finally, Argus lifted their price target on Amgen from $300.00 to $340.00 and gave the company a “buy” rating in a research report on Thursday. Ten analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat.com, Amgen currently has a consensus rating of “Moderate Buy” and a consensus target price of $307.35.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.